A Phase 3 interventional study of Fulvestrant and Alpelisib in Breast Cancer, sponsored by Novartis Pharmaceuticals. Completed at 197 sites in 31 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-02-13.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies testing alpelisib in Breast Neoplasms — 3 open to participants now, 12 under way, 2 of them phase 3. Alpelisib · Breast Neoplasms.
Among the 38 studies testing alpelisib in Breast Neoplasms, this one has the largest enrollment, is one of 3 that started in 2015, is one of 5 in phase 3, and was the 16th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.
Browse Breast Neoplasms studies →3 of the 38 studies testing alpelisib in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
The Methodist Hospital Research Institute · Sites in United States
Ages 18+
Novartis Pharmaceuticals
By country, each count listing its studies:
Alpelisib: first FDA approval 2019 (PIQRAY), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, alpelisib is the treatment under test here. Read study by study →
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 19 · Phase 3 5
First in 2010; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 572 is above the median of 72 across 10,903 interventional studies indexed under Breast Neoplasms.
Median enrollment 44 across the 38 interventional studies. Of the 25 that completed or were terminated, 10 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 38 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
199 studies in Breast Neoplasms by Novartis: 16 open now, 30 under way, 4 of them phase 3. Of 160 finished, 74 (46%) have results posted.
Among the 199 studies in Breast Neoplasms by Novartis, this one is the 17th largest by enrollment of the 155 interventional ones that give a count, is one of 3 that started in 2015, is one of 45 in phase 3, and was the 120th registered.
Novartis’s Breast Neoplasms studies by the year they started, since 1998.
7 of the studies testing alpelisib in Breast Neoplasms that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05038735Phase 3Novartis PharmaceuticalsStudy to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor. | 2027-01-28 |
| NCT04208178Phase 3Novartis PharmaceuticalsStudy of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation | 2027-02-26 |
| NCT05660083The Methodist Hospital Research InstituteAlpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC) | 2026-12-01 |
| NCT04544189Novartis PharmaceuticalsStudy Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer | 2027-01-29 |
| NCT01872260Novartis PharmaceuticalsStudy of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer | 2027-02-26 |
Add all 7 to your calendar (.ics) → With an account.
Among the 38 studies testing alpelisib in Breast Neoplasms, from their registry updates:
Among Novartis’s 199 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
To determine whether treatment with alpelisib plus fulvestrant prolonged progression-free survival (PFS) compared to fulvestrant and placebo in men and postmenopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor-2 (HER2)-negative advanced breast cancer, who received prior treatment with an aromatase Inhibitor (AI) either as (neo)adjuvant or for advanced disease.
This was a randomized, double-blind, placebo-controlled, international multicenter Phase III study that evaluated the efficacy and safety of treatment with alpelisib plus fulvestrant versus placebo plus fulvestrant in men and postmenopausal women with HR-positive, HER2-negative advanced breast cancer which had progressed on or after AI treatment.
Subjects were allocated to either the PIK3CA mutant or PIK3CA non-mutant cohort, based on central testing of hotspot-mutations in tumor tissue. Subjects with unknown results were not eligible. Within each cohort, subjects were randomized in a 1:1 ratio to receive either alpelisib 300 mg orally once daily (q.d.), in combination with fulvestrant 500 mg intramuscular (i.m.) on Days 1 and 15 of Cycle 1 and Day 1 of a 28-day cycle thereafter, or placebo daily in combination with fulvestrant 500 mg following the same treatment regimen.
Subjects were treated until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason. All subjects who discontinued study treatment were followed for safety, until 30 days after last study treatment administration, except in the case of death, loss to follow-up, or withdrawal of consent.
Subjects who discontinued study treatment for reasons other than disease progression or withdrawal of consent, were followed until disease progression, death, withdrawal of consent, loss to follow-up, or subject/guardian decision (post-treatment efficacy follow-up).
Finally, all subjects were followed for survival after discontinuation of study treatment and tumor evaluations until the subject's death, loss to follow-up, or withdrawal of consent for survival follow-up (post-treatment survival follow-up)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects treated with alpelisib (300 mg; oral; once daily) in combination with fulvestrant (500 mg; intramuscular injection on Day 1 and Day 15 of Cycle 1, and then Day 1 of each subsequent 28-day cycle)
Drug: Fulvestrant · Drug: Alpelisib
Subjects were treated with placebo (300 mg; oral; once daily) in combination with fulvestrant (500 mg; intramuscular injection on Day 1 and Day 15 of Cycle 1, and then Day 1 of each subsequent 28-day cycle)
Drug: Fulvestrant · Drug: Placebo
500 mg of fulvestrant administered via intramuscular injection on Day 1 and Day 15 of Cycle 1, and then Day 1 of each subsequent 28-day cycle
300 mg of alpelisib tablets for oral use administered once daily
Also known as: BYL719
300 mg of placebo tablets for oral use administered once daily
Progression-free Survival (PFS) Per Investigator Assessment in the PIK3CA Mutant Cohort
PFS was defined as the time from the date of randomization to the date of the first documented progression or death due to any cause. PFS was assessed via a local radiology assessment according to RECIST 1.1. If a patient did not have an event, PFS was censored at the date of last adequate tumor assessment. The PFS distribution was estimated using Kaplan-Meier methodology. Progression was defined as at least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: Once approximately 243 PFS events in the PIK3CA mutant cohort had been observed, up to 33.3 months
Overall Survival (OS) in the PIK3CA Mutant Cohort
OS was defined as the time from date of randomization to date of death due to any cause. If a patient was not known to have died, survival was censored at the date of last known date patient alive. The OS distribution was estimated using Kaplan-Meier methodology.
Time frame: Once approximately 178 deaths in the PIK3CA mutant cohort had been observed, up to 55.7 months
PFS Per Investigator Assessment in the PIK3CA Non-mutant Cohort
PFS was defined as the time from the date of randomization to the date of the first documented progression or death due to any cause. PFS was assessed via a local radiology assessment according to RECIST 1.1. If a patient did not have an event, PFS was censored at the date of last adequate tumor assessment. The PFS distribution was estimated using Kaplan-Meier methodology. Progression was defined as at least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: Up to 56.4 months
OS in the PIK3CA Non-mutant Cohort
OS was defined as the time from date of randomization to date of death due to any cause. If a patient was not known to have died, survival was censored at the date of last known date patient alive. The OS distribution was estimated using Kaplan-Meier methodology.
Time frame: Up to 56.4 months
Overall Response Rate (ORR) Per Investigator Assessment
ORR was defined as the percentage of patients with best overall response of complete response (CR) or partial response (PR) based on local investigator's assessment according to RECIST 1.1. CR: Disappearance of all non-nodal target and non-target lesions. In addition, any pathological lymph nodes assigned as target and non-target lesions must have a reduction in short axis to \< 10 mm. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.
Time frame: Up to 56.4 months
Clinical Benefit Rate (CBR) Per Investigator Assessment
Clinical benefit rate was defined as the percentage of patients with a best overall response of CR or PR or stable disease (SD) or Non-CR/Non-PD lasting more than 24 weeks based on local investigator assessment according to RECIST 1.1. CR: Disappearance of all non-nodal target and non-target lesions. In addition, any pathological lymph nodes assigned as target and non-target lesions must have a reduction in short axis to \< 10 mm. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. SD: Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progressive disease.
Time frame: Up to 56.4 months
Time to Definitive Deterioration of Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) Score From Baseline
ECOG PS categorized patients based on their ability to perform daily activities and self-care, with scores ranging from 0 to 5. A score of 0 indicated no restrictions in activity, while higher scores indicated increasing limitations. Time to definitive deterioration of ECOG PS by one score was defined as the time from the date of randomization to the date of the event, defined as experiencing at least one score lower than the baseline. A deterioration was considered definitive if no improvements in the ECOG PS were observed at a subsequent time. The Kaplan-Meier method was used to estimate the distribution. Patients receiving any further therapy prior to definitive worsening were censored at their date of last assessment prior to start of therapy. Patients that had not worsened at the data cutoff point were censored at the date of last assessment.
Time frame: From baseline up to 56.4 months
Time to 10% Deterioration in the Global Health Status (GHS) /Quality of Life (QOL) Scale Score of the European Organization for Research and Treatment of Cancer's Core Quality of Life Questionnaire (EORTC QLQ-C30)
The EORTC QLQ-C30 is a questionnaire that includes 5 functional scales, 3 symptom scales, 1 GHS/QoL scale, and 6 single items. GHS/QoL scale score ranges between 0 and 100. A high score for GHS/QoL represents better functioning or QoL.The time to definitive 10% deterioration was defined as the time from the date of randomization to the date of event, which was defined as at least 10% relative to baseline worsening of the GHS/QoL score (without further improvement above the threshold) or death due to any cause. The Kaplan-Meier method was used to estimate the distribution. If a patient had not had an event, time to deterioration was censored at the date of the last adequate QoL evaluation.
Time frame: From baseline up to 55.7 months
Change From Baseline in the GHS/QOL Scale Score of the EORTC QLQ-C30
The EORTC QLQ-C30 is a questionnaire that includes 5 functional scales, 3 symptom scales, 1 GHS/QoL scale, and 6 single items. GHS/QoL scale score ranges between 0 and 100. A high score for GHS/QoL represents better functioning or QoL.The change from baseline in the GHS/QoL score was assessed. A positive change from baseline indicated improvement. For each cohort, this analysis only included assessments up to the time point where there were at least 10 patients on each of the 2 treatment groups.
Time frame: Baseline, every 8 weeks after randomization during the first 18 months and thereafter every 12 weeks, up to 120 weeks.
Trough Plasma Concentration of Alpelisib
Pre-dose plasma concentrations of alpelisib were assessed. Only participants randomized to the alpelisib + fulvestrant arm were included in this analysis.
Time frame: Day 8 and Day 15 of Cycle 1, then Day 1 of Cycles 2, 4, 6 and 8. Cycle = 28 days
Trough Plasma Concentration of Fulvestrant
Pre-dose plasma concentrations of fulvestrant were assessed.
Time frame: Day 15 of Cycle 1, then Day 1 of Cycles 2, 4, 6 and 8. Cycle = 28 days
PFS Per Investigator Criteria in Subjects With PIK3CA Mutation Status Measured in ctDNA at Baseline
PFS was defined as the time from the date of randomization to the date of the first documented progression or death due to any cause. PFS was assessed via a local radiology assessment according to RECIST 1.1. If a patient did not have an event, PFS was censored at the date of last adequate tumor assessment. The PFS distribution was estimated using Kaplan-Meier methodology. Subjects were analyzed according to the PIK3CA mutation status (mutant or non-mutant) as identified using plasma ctDNA. Progression was defined as at least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: From baseline up to 56.4 months
Updated PFS Per Investigator Assessment in the PIK3CA Mutant Cohort (Longer Follow-up)
PFS was defined as the time from the date of randomization to the date of the first documented progression or death due to any cause. PFS was assessed via a local radiology assessment according to RECIST 1.1. If a patient did not have an event, PFS was censored at the date of last adequate tumor assessment. The PFS distribution was estimated using Kaplan-Meier methodology. This analysis was conducted at the time of the final OS analysis (when approximately 178 deaths in the PIK3CA mutant cohort had been achieved) and includes a longer follow-up time. Progression was defined as at least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: Up to 55.7 months
Participants were enrolled in 198 centers across 31 countries
| Milestone | Alpelisib + Fulvestrant | Placebo + Fulvestrant |
|---|---|---|
| Started | 284 | 288 |
| Treated | 284 | 287 |
| Pik3ca mutant cohort by tumor tissue | 169 | 172 |
| Pik3ca non-mutant cohort by tumor tissue | 115 | 116 |
| Pik3ca mutant cohort by ctdna | 92 | 94 |
| Pik3ca non-mutant cohort by ctdna | 181 | 182 |
| Completed | 0 | 0 |
| Not completed | 284 | 288 |
| Withdrew: Progressive disease | 207 | 240 |
| Withdrew: Subject/guardian decision | 24 | 11 |
| Withdrew: Physician decision | 29 | 22 |
| Withdrew: Adverse event | 14 | 4 |
| Withdrew: Death | 4 | 4 |
| Withdrew: Protocol deviation | 5 | 7 |
| Withdrew: Sponsor decision | 1 | 0 |
PFS was defined as the time from the date of randomization to the date of the first documented progression or death due to any cause. PFS was assessed via a local radiology assessment according to RECIST 1.1. If a patient did not have an event, PFS was censored at the date of last adequate tumor assessment. The PFS distribution was estimated using Kaplan-Meier methodology. Progression was defined as at least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
| Months | PIK3CA Mutant Cohort by Tumor Tissue: Alpelisib + Fulvestrant | PIK3CA Mutant Cohort by Tumor Tissue: Placebo + Fulvestrant |
|---|---|---|
| Progression-free Survival (PFS) Per Investigator Assessment in the PIK3CA Mutant Cohort | 11.0 (7.49 to 14.52) | 5.7 (3.65 to 7.36) |
OS was defined as the time from date of randomization to date of death due to any cause. If a patient was not known to have died, survival was censored at the date of last known date patient alive. The OS distribution was estimated using Kaplan-Meier methodology.
| Months | PIK3CA Mutant Cohort by Tumor Tissue: Alpelisib + Fulvestrant | PIK3CA Mutant Cohort by Tumor Tissue: Placebo + Fulvestrant |
|---|---|---|
| Overall Survival (OS) in the PIK3CA Mutant Cohort | 39.3 (34.10 to 44.85) | 31.4 (26.78 to 41.30) |
PFS was defined as the time from the date of randomization to the date of the first documented progression or death due to any cause. PFS was assessed via a local radiology assessment according to RECIST 1.1. If a patient did not have an event, PFS was censored at the date of last adequate tumor assessment. The PFS distribution was estimated using Kaplan-Meier methodology. Progression was defined as at least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
| Months | PIK3CA Non-mutant Cohort by Tumor Tissue: Alpelisib + Fulvestrant | PIK3CA Non-mutant Cohort by Tumor Tissue: Placebo + Fulvestrant |
|---|---|---|
| PFS Per Investigator Assessment in the PIK3CA Non-mutant Cohort | 7.43 (5.55 to 10.84) | 7.23 (5.06 to 9.17) |
OS was defined as the time from date of randomization to date of death due to any cause. If a patient was not known to have died, survival was censored at the date of last known date patient alive. The OS distribution was estimated using Kaplan-Meier methodology.
| Months | PIK3CA Non-mutant Cohort by Tumor Tissue: Alpelisib + Fulvestrant | PIK3CA Non-mutant Cohort by Tumor Tissue: Placebo + Fulvestrant |
|---|---|---|
| OS in the PIK3CA Non-mutant Cohort | 37.29 (27.89 to 45.47) | 34.30 (26.81 to 39.03) |
ORR was defined as the percentage of patients with best overall response of complete response (CR) or partial response (PR) based on local investigator's assessment according to RECIST 1.1. CR: Disappearance of all non-nodal target and non-target lesions. In addition, any pathological lymph nodes assigned as target and non-target lesions must have a reduction in short axis to \< 10 mm. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.
| Percentage of participants | PIK3CA Mutant Cohort by Tumor Tissue: Alpelisib + Fulvestrant | PIK3CA Mutant Cohort by Tumor Tissue: Placebo + Fulvestrant | PIK3CA Non-mutant Cohort by Tumor Tissue: Alpelisib + Fulvestrant | PIK3CA Non-mutant Cohort by Tumor Tissue: Placebo + Fulvestrant |
|---|---|---|---|---|
| Overall Response Rate (ORR) Per Investigator Assessment | 26.6 (20.1 to 34.0) | 13.4 (8.7 to 19.4) | 20.9 (13.9 to 29.4) | 12.9 (7.4 to 20.4) |
Clinical benefit rate was defined as the percentage of patients with a best overall response of CR or PR or stable disease (SD) or Non-CR/Non-PD lasting more than 24 weeks based on local investigator assessment according to RECIST 1.1. CR: Disappearance of all non-nodal target and non-target lesions. In addition, any pathological lymph nodes assigned as target and non-target lesions must have a reduction in short axis to \< 10 mm. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. SD: Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progressive disease.
| Percentage of participants | PIK3CA Mutant Cohort by Tumor Tissue: Alpelisib + Fulvestrant | PIK3CA Mutant Cohort by Tumor Tissue: Placebo + Fulvestrant | PIK3CA Non-mutant Cohort by Tumor Tissue: Alpelisib + Fulvestrant | PIK3CA Non-mutant Cohort by Tumor Tissue: Placebo + Fulvestrant |
|---|---|---|---|---|
| Clinical Benefit Rate (CBR) Per Investigator Assessment | 61.5 (53.8 to 68.9) | 44.8 (37.2 to 52.5) | 53.9 (44.4 to 63.2) | 49.1 (39.7 to 58.6) |
ECOG PS categorized patients based on their ability to perform daily activities and self-care, with scores ranging from 0 to 5. A score of 0 indicated no restrictions in activity, while higher scores indicated increasing limitations. Time to definitive deterioration of ECOG PS by one score was defined as the time from the date of randomization to the date of the event, defined as experiencing at least one score lower than the baseline. A deterioration was considered definitive if no improvements in the ECOG PS were observed at a subsequent time. The Kaplan-Meier method was used to estimate the distribution. Patients receiving any further therapy prior to definitive worsening were censored at their date of last assessment prior to start of therapy. Patients that had not worsened at the data cutoff point were censored at the date of last assessment.
| Months | PIK3CA Mutant Cohort by Tumor Tissue: Alpelisib + Fulvestrant | PIK3CA Mutant Cohort by Tumor Tissue: Placebo + Fulvestrant | PIK3CA Non-mutant Cohort by Tumor Tissue: Alpelisib + Fulvestrant | PIK3CA Non-mutant Cohort by Tumor Tissue: Placebo + Fulvestrant |
|---|---|---|---|---|
| Time to Definitive Deterioration of Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) Score From Baseline | 34.07 (26.32 to NA) | NA (22.11 to NA) | NA (13.83 to NA) | 40.44 (18.46 to 47.21) |
The EORTC QLQ-C30 is a questionnaire that includes 5 functional scales, 3 symptom scales, 1 GHS/QoL scale, and 6 single items. GHS/QoL scale score ranges between 0 and 100. A high score for GHS/QoL represents better functioning or QoL.The time to definitive 10% deterioration was defined as the time from the date of randomization to the date of event, which was defined as at least 10% relative to baseline worsening of the GHS/QoL score (without further improvement above the threshold) or death due to any cause. The Kaplan-Meier method was used to estimate the distribution. If a patient had not had an event, time to deterioration was censored at the date of the last adequate QoL evaluation.
| Months | PIK3CA Mutant Cohort by Tumor Tissue: Alpelisib + Fulvestrant | PIK3CA Mutant Cohort by Tumor Tissue: Placebo + Fulvestrant | PIK3CA Non-mutant Cohort by Tumor Tissue: Alpelisib + Fulvestrant | PIK3CA Non-mutant Cohort by Tumor Tissue: Placebo + Fulvestrant |
|---|---|---|---|---|
| Time to 10% Deterioration in the Global Health Status (GHS) /Quality of Life (QOL) Scale Score of the European Organization for Research and Treatment of Cancer's Core Quality of Life Questionnaire (EORTC QLQ-C30) | 18.14 (14.55 to 28.68) | 19.98 (11.50 to 25.59) | 7.39 (5.62 to NA) | 9.23 (3.94 to 13.17) |
The EORTC QLQ-C30 is a questionnaire that includes 5 functional scales, 3 symptom scales, 1 GHS/QoL scale, and 6 single items. GHS/QoL scale score ranges between 0 and 100. A high score for GHS/QoL represents better functioning or QoL.The change from baseline in the GHS/QoL score was assessed. A positive change from baseline indicated improvement. For each cohort, this analysis only included assessments up to the time point where there were at least 10 patients on each of the 2 treatment groups.
| Score on a Scale | PIK3CA Mutant Cohort by Tumor Tissue: Alpelisib + Fulvestrant | PIK3CA Mutant Cohort by Tumor Tissue: Placebo + Fulvestrant | PIK3CA Non-mutant Cohort by Tumor Tissue: Alpelisib + Fulvestrant | PIK3CA Non-mutant Cohort by Tumor Tissue: Placebo + Fulvestrant |
|---|---|---|---|---|
| Week 8 | -2.477 ± 2.286 | -0.369 ± 2.324 | 1.524 ± 2.578 | 2.698 ± 2.601 |
| Week 16 | -1.796 ± 2.349 | -2.685 ± 2.455 | 2.866 ± 2.809 | 1.700 ± 2.835 |
| Week 24 | -3.010 ± 2.415 | -0.337 ± 2.587 | 1.383 ± 3.087 | 4.909 ± 3.385 |
| Week 32 | -2.802 ± 2.519 | -0.891 ± 2.646 | 1.063 ± 3.420 | 4.345 ± 3.731 |
| Week 40 | -2.815 ± 2.581 | -1.854 ± 2.739 | 13.232 ± 4.783 | 4.923 ± 4.003 |
| Week 48 | -3.635 ± 2.621 | -1.460 ± 2.853 | — | — |
| Week 56 | -1.617 ± 2.701 | 0.248 ± 2.935 | — | — |
| Week 64 | -1.937 ± 2.835 | -1.979 ± 2.984 | — | — |
| Week 72 | -2.525 ± 2.823 | -1.526 ± 3.098 | — | — |
| Week 84 | -1.135 ± 2.958 | -1.495 ± 3.143 | — | — |
| Week 96 | -3.869 ± 3.054 | -3.581 ± 3.423 | — | — |
| Week 108 | -2.158 ± 3.328 | -2.068 ± 3.609 | — | — |
| Week 120 | -2.928 ± 3.251 | -2.593 ± 3.868 | — | — |
Pre-dose plasma concentrations of alpelisib were assessed. Only participants randomized to the alpelisib + fulvestrant arm were included in this analysis.
| nanogram (ng)/ milliliter (mL) | Alpelisib + Fulvestrant |
|---|---|
| Cycle 1 Day 8 | 424 ± 41.1 |
| Cycle 1 Day 15 | 468 ± 57.6 |
| Cycle 2 Day 1 | 436 ± 53.4 |
| Cycle 4 Day 1 | 458 ± 69.4 |
| Cycle 6 Day 1 | 418 ± 57.1 |
| Cycle 8 Day 1 | 469 ± 58.3 |
Pre-dose plasma concentrations of fulvestrant were assessed.
| nanogram (ng)/ milliliter (mL) | Alpelisib + Fulvestrant | Placebo + Fulvestrant |
|---|---|---|
| Cycle 1 Day 15 | 10.8 ± 43.5 | 10.3 ± 51.0 |
| Cycle 2 Day 1 | 14.0 ± 39.7 | 14.7 ± 41.2 |
| Cycle 4 Day 1 | 11.5 ± 32.2 | 12.2 ± 29.8 |
| Cycle 6 Day 1 | 12.6 ± 30.5 | 14.0 ± 24.2 |
| Cycle 8 Day 1 | 13.5 ± 35.2 | 14.7 ± 23.2 |
PFS was defined as the time from the date of randomization to the date of the first documented progression or death due to any cause. PFS was assessed via a local radiology assessment according to RECIST 1.1. If a patient did not have an event, PFS was censored at the date of last adequate tumor assessment. The PFS distribution was estimated using Kaplan-Meier methodology. Subjects were analyzed according to the PIK3CA mutation status (mutant or non-mutant) as identified using plasma ctDNA. Progression was defined as at least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
| Months | PIK3CA Mutant Determined by ctDNA: Alpelisib + Fulvestrant | PIK3CA Mutant Determined by ctDNA: Placebo + Fulvestrant | PIK3CA Non-mutant Determined by ctDNA: Alpelisib + Fulvestrant | PIK3CA Non-mutant Determined by ctDNA: Placebo + Fulvestrant |
|---|---|---|---|---|
| PFS Per Investigator Criteria in Subjects With PIK3CA Mutation Status Measured in ctDNA at Baseline | 10.9 (7.03 to 15.28) | 3.7 (2.27 to 6.11) | 9.0 (7.23 to 11.01) | 7.4 (5.55 to 9.20) |
Pre-treatment deaths were collected from randomization to the day before first dose of study medication. On-treatment deaths were collected from start of treatment to 30 days after last dose of study medication. Post-treatment survival follow-up deaths were collected from day 31 after last dose of study treatment to end of study.
| Participants | Alpelisib + Fulvestrant | Placebo + Fulvestrant |
|---|---|---|
| Pre-treatment | 0 | 0 |
| On-treatment | 9 | 12 |
| Post-treatment survival follow-up | 151 | 156 |
| All deaths | 160 | 168 |
PFS was defined as the time from the date of randomization to the date of the first documented progression or death due to any cause. PFS was assessed via a local radiology assessment according to RECIST 1.1. If a patient did not have an event, PFS was censored at the date of last adequate tumor assessment. The PFS distribution was estimated using Kaplan-Meier methodology. This analysis was conducted at the time of the final OS analysis (when approximately 178 deaths in the PIK3CA mutant cohort had been achieved) and includes a longer follow-up time. Progression was defined as at least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
| Months | PIK3CA Mutant Cohort by Tumor Tissue: Alpelisib + Fulvestrant | PIK3CA Mutant Cohort by Tumor Tissue: Placebo + Fulvestrant |
|---|---|---|
| Updated PFS Per Investigator Assessment in the PIK3CA Mutant Cohort (Longer Follow-up) | 10.97 (7.49 to 14.52) | 5.65 (3.65 to 7.36) |
Collected over All-cause mortality: from randomization up to approx. 6.5 years, including post-treatment survival follow up period. Serious and Other Adverse Events: from first dose of study treatment until 30 days after last dose up to approx. 6.5 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Alpelisib + Fulvestrant | 9/284 (3.2%) | 110/284 (38.7%) | 280/284 (98.6%) |
| Placebo + Fulvestrant | 12/288 (4.2%) | 54/287 (18.8%) | 244/287 (85%) |
| Alpelisib + Fulvestrant (Post-treatment Survival Follow-up) | 151/275 (54.9%) | — | — |
| Placebo + Fulvestrant (Post-treatment Survival Follow-up) | 156/275 (56.7%) | — | — |
| Event | Alpelisib + Fulvestrant | Placebo + Fulvestrant | Alpelisib + Fulvestrant (Post-treatment Survival Follow-up) | Placebo + Fulvestrant (Post-treatment Survival Follow-up) |
|---|---|---|---|---|
| HyperglycaemiaMetabolism and nutrition disorders | 28/284 | 0/287 | — | — |
| DiarrhoeaGastrointestinal disorders | 9/284 | 0/287 | — | — |
| Osteonecrosis of jawMusculoskeletal and connective tissue disorders | 9/284 | 2/287 | — | — |
| AnaemiaBlood and lymphatic system disorders | 6/284 | 0/287 | — | — |
| Abdominal painGastrointestinal disorders | 6/284 | 2/287 | — | — |
| Acute kidney injuryRenal and urinary disorders | 6/284 | 1/287 | — | — |
| PneumoniaInfections and infestations | 3/284 | 6/287 | — | — |
| NauseaGastrointestinal disorders | 5/284 | 2/287 | — | — |
| VomitingGastrointestinal disorders | 5/284 | 3/287 | — | — |
| RashSkin and subcutaneous tissue disorders | 5/284 | 0/287 | — | — |
| Event | Alpelisib + Fulvestrant | Placebo + Fulvestrant | Alpelisib + Fulvestrant (Post-treatment Survival Follow-up) | Placebo + Fulvestrant (Post-treatment Survival Follow-up) |
|---|---|---|---|---|
| HyperglycaemiaMetabolism and nutrition disorders | 182/284 | 27/287 | — | — |
| DiarrhoeaGastrointestinal disorders | 167/284 | 48/287 | — | — |
| NauseaGastrointestinal disorders | 133/284 | 64/287 | — | — |
| Decreased appetiteMetabolism and nutrition disorders | 103/284 | 30/287 | — | — |
| RashSkin and subcutaneous tissue disorders | 101/284 | 20/287 | — | — |
| VomitingGastrointestinal disorders | 80/284 | 27/287 | — | — |
| Weight decreasedInvestigations | 79/284 | 7/287 | — | — |
| FatigueGeneral disorders | 73/284 | 51/287 | — | — |
| StomatitisGastrointestinal disorders | 70/284 | 20/287 | — | — |
| AstheniaGeneral disorders | 64/284 | 40/287 | — | — |
| Age, Continuous(Years) | Alpelisib + Fulvestrant | Placebo + Fulvestrant | Total |
|---|---|---|---|
| Mean | 62.6 ± 9.74 | 63.3 ± 10.26 | 63.0 ± 10.00 |
| Sex: Female, Male(Participants) | Alpelisib + Fulvestrant | Placebo + Fulvestrant | Total |
|---|---|---|---|
| Female | 283 | 288 | 571 |
| Male | 1 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Alpelisib + Fulvestrant | Placebo + Fulvestrant | Total |
|---|---|---|---|
| White | 199 | 178 | 377 |
| Asian | 59 | 66 | 125 |
| Black or African American | 2 | 6 | 8 |
| American Indian or Alaska | 1 | 4 | 5 |
| Other | 9 | 17 | 26 |
| Unknown | 14 | 17 | 31 |
Showing the first 100 of 197 sites across 31 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Jul 2015 to primary completion in Jun 2018, 34 months.
Results were first posted in Aug 2019, 1 year 2 months after primary completion. A results delay was requested in Jul 2018.
Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 34 months is below that.
Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alpelisib